A shRNA for inhibiting yak PIWIL1 gene expression, construction vector and application thereof

By constructing shRNA that inhibits the expression of PIWIL1 gene and transfecting yak testicular interstitial cells with recombinant lentivirus, inhibiting the expression of STAR and CYP11A1, the problem of testosterone synthesis ability of yak testicular interstitial cells is solved, and an important target for studying testicular development regulation is provided. , significantly affects the reproductive performance of yaks.

CN117363617BInactive Publication Date: 2024-11-22LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311304090.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-09
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The PIWIL1 gene is not clear in the study of the development mechanism of yak testicles, and the prior art is difficult to effectively inhibit the testosterone synthesis ability of yak testicle interstitial cells.

Method used

The shRNA that inhibits the expression of yak PIWIL1 gene was constructed and transfected with yak testicular interstitial cells through recombinant lentiviruses, inhibiting the expression of STAR and CYP11A1, thereby interfering with testosterone synthesis.

Benefits of technology

It has achieved stable interference with PIWIL1 gene expression, significantly inhibited the testosterone synthesis ability of yak testicular interstitial cells, provided a target for yak reproductive performance, and is of great significance to the mechanism of testicular development regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117363617B_ABST
    Figure CN117363617B_ABST
Patent Text Reader

Abstract

The present invention discloses a siRNA, shRNA and its encoding gene sequence, construction vector, recombinant lentivirus and application for inhibiting the expression of yak PIWIL1 gene, and belongs to the field of molecular biology technology. The sequence of the siRNA is shown in SEQ ID No.1; the sequence of the shRNA is shown in SEQ ID No.2. The present invention constructs the PIWIL1 gene interference lentivirus of yak for the first time, which can efficiently and conveniently infect yak Leydig cells and can stably interfere with the expression of PIWIL1 gene in Leydig cells. Stable interference with PIWIL1 gene expression can inhibit the testosterone synthesis ability of yak Leydig cells, thereby providing a very effective target for the reproductive performance of male yaks, which is of great significance for studying the regulatory mechanism of yak testicular development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular biology, and in particular relates to a shRNA for inhibiting the expression of yak PIWIL1 gene, a constructed vector and an application thereof. Background Art

[0002] PIWI protein was first discovered during the study of asymmetric division of female Drosophila melanogaster germ stem cells. It is a DNA sequence that has the functions of mediating transposon silencing, transcriptional silencing and translation inhibition. It was originally named PIWI gene. Subsequently, researchers discovered two PIWI homologous genes, Prg-1 and Prg-2, in Caenorhabditis elegans, which play an important role in the self-renewal of germ stem cells. Since then, PIWI protein has been discovered in many animals, but the number of PIWI family members in different species is different. For example, in cattle, there are 4 PIWI family members, namely PIWIL1, PIWIL2, PIWIL3 and PIWIL4. PIWI protein plays an important role in epigenetic regulation, transposable element silencing, genome integrity protection, gametogenesis and piRNA biogenesis.

[0003] Initially, it was believed that PIWI proteins were only expressed in the germ cell line and were involved in the development, differentiation and maintenance of germ cell stability. PIWI proteins play an important role in mammalian oogenesis and early embryonic development. However, the expression pattern of PIWI proteins has certain developmental process and spatial specificity, suggesting that germ cell development may be regulated by a mutually coordinated rather than redundant pattern.

[0004] In recent years, studies have shown that PIWI proteins not only play a role in transposon silencing, but also play a vital role in regulating gene expression in other tissues and cells. PIWI proteins are distributed in various organs such as lungs, heart, kidneys, brain and pancreas. At present, the role of PIWI proteins in organogenesis is still unclear. However, studies in human embryonic lungs have found that the expression of the PIWIL1 gene increased significantly from the 6th to the 9th week of embryonic period, and then began to decline from the 9th week. During the development of the cerebral cortex, PIWIL1 is mainly involved in neuronal differentiation and radial migration, and is essential for the normal development of the brain. In particular, PIWIL1 regulates the function of cerebral cortical neurons by regulating the expression of microtubule-associated proteins. At the same time, there are also studies showing that the expression of PIWI proteins is significantly increased when certain tissues are lesioned. Recent studies on fruit flies and rats have found that PIWI family members are related to metabolic functions. In adult fruit fly adipocytes, PIWI proteins play an important role in maintaining the integrity of genomic regions related to fat metabolism.

[0005] In summary, PIWIL1 can act as an epigenetic activator and is essential for reproductive development. Its main function has been relatively clear in the fields of medicine and model animals, but its relationship with testicular development in yaks is still unclear. Summary of the invention

[0006] In order to solve at least one of the above technical problems, the inventors constructed a PIWIL1 interfering lentivirus and transfected yak Leydig cells. Unexpectedly, they found that stable interference with PIWIL1 gene expression can inhibit the testosterone synthesis ability of yak Leydig cells, thereby completing the present invention.

[0007] In a first aspect, the present invention provides an siRNA for inhibiting the expression of yak PIWIL1 gene, wherein the sequence of the siRNA is shown as SEQ ID No.1.

[0008] The second aspect of the present invention provides a shRNA sequence that can form the siRNA described in the first aspect of the present invention, and the sequence of the shRNA is shown as SEQ ID No.2.

[0009] The third aspect of the present invention provides a gene sequence encoding the shRNA described in the second aspect of the present invention, and the gene sequence is shown as SEQ ID No.3.

[0010] The fourth aspect of the present invention provides a construction vector comprising the gene sequence described in the third aspect of the present invention.

[0011] The fifth aspect of the present invention provides a recombinant lentivirus, comprising the vector described in the thirty-fourth aspect of the present invention.

[0012] In some embodiments of the present invention, the recombinant lentivirus is obtained by co-transfecting mammalian cells with the vector of claim 8, a viral packaging helper plasmid psPAX2, and a viral packaging helper plasmid pMD2.G.

[0013] The sixth aspect of the present invention provides the use of the siRNA described in the first aspect of the present invention, the shRNA described in the second aspect of the present invention, the gene sequence described in the third aspect of the present invention, the construction vector described in the fourth aspect of the present invention and / or the recombinant lentivirus described in the fifth aspect of the present invention in the preparation of an inhibitor for inhibiting the testosterone synthesis ability of yaks.

[0014] In some embodiments of the present invention, the inhibitor inhibits the testosterone synthesis ability of yaks by inhibiting the expression of STAR and CYP11A1.

[0015] Beneficial effects of the present invention

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention constructs for the first time a yak PIWIL1 gene interference lentivirus, which can efficiently and conveniently infect yak Leydig cells and can stably interfere with the expression of the PIWIL1 gene in the Leydig cells.

[0018] Stable interference with PIWIL1 gene expression can inhibit the testosterone synthesis ability of yak Leydig cells, thereby providing a very effective target for the reproductive performance of male yaks, which is of great significance for studying the regulatory mechanism of testicular development in yaks. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The results show that the PIWIL1 gene interference lentivirus constructed in the embodiment of the present invention inhibits PIWIL1 in Leydig cells. A: Western Blot detection diagram; B: protein expression bar graph.

[0020] Figure 2 The results show that the PIWIL1 gene interference lentivirus constructed in the present invention inhibits STAR and CYP11A1 proteins in Leydig cells. A: gel detection diagram; B: protein expression bar graph. DETAILED DESCRIPTION

[0021] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.

[0022] Example

[0023] The following examples are used to demonstrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors that can be used to implement the present invention and therefore can be considered as preferred embodiments of the present invention. However, it will be appreciated by those skilled in the art based on this specification that many modifications may be made to the specific embodiments disclosed herein and still achieve the same or similar results without departing from the spirit or scope of the present invention.

[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, and the disclosure and materials cited therein are hereby incorporated by reference.

[0025] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many technical equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the claims.

[0026] The experimental methods in the following examples are conventional methods unless otherwise specified. The instruments and equipment used in the following examples are conventional laboratory instruments and equipment unless otherwise specified; the experimental materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified.

[0027] Example 1 Construction of yak PIWIL1 gene overexpression vector and silencing lentivirus

[0028] 1. Interference sequence design

[0029] According to the bovine PIWIL1 sequence information in the GenBank nucleotide sequence database (XM No.: 005889573.2, CDS: 2586 bp), the interference sequence siRNA was designed, including a 22-base sequence, and the specific sequence is as follows:

[0030] GAACCUAGAUCAUGUGGAAAGA(SEQ ID No.1)

[0031] Based on this, the shRNA sequence that can form the siRNA sequence is designed as follows:

[0032] GAACCUAGAUCAUGUGGAAAGAtctcttuaaTCTTTCACATUATCTAUUTTC(SEQ ID No.2)

[0033] A gene sequence encoding the shRNA was designed for constructing a vector. The specific sequence is as follows:

[0034] ccgGAACCTAGATCATGTGAAAGAttcaagagaTCTTTCACATGATCTAGGTTCtttt(SEQ IDNo.3)

[0035] Among them, ccg is the start sequence and ttttt is the stop sequence.

[0036] 2. Vector Construction

[0037] The gene sequence of the yak PIWIL1 interference sequence (SEQ ID No. 3) was artificially synthesized, and restriction sites BamH I and EcoR I were added to the 5' end and 3' end of the sequence, respectively.

[0038] First, the viral plasmid vector (pLVX-IRES-Puro) was linearized by restriction digestion, and the successfully linearized plasmid was recovered. The reaction system was: 2.0 μg of pLVX-IRES-Puro plasmid, 0.5 μL of EcoR1, 0.5 μL of BamHI, 2 μL of 10×FastDigest Buffer, and 20 μL of high-pressure water. Enzyme digestion was performed at 37°C for 30 min.

[0039] Then, the artificially synthesized gene sequence encoding shRNA was double-digested (BamHI and EcoRI), and the digestion system was plasmid 1 μg, endonuclease EcoRI 1 μL, endonuclease BamHI 1 μL, Buffer 2 μL, and high-pressure water supplemented to 20 μL. Digestion was performed at 37°C for 30 minutes.

[0040] The linear vector obtained after enzyme digestion was connected with the gene sequence encoding shRNA to obtain the pLVX-IRES-puro-PIWIL1 lentiviral vector. The connection system was: 1μL of linear vector, 1μL of gene sequence encoding shRNA, 3μL of oligo annealing product, 1μL of T4 Buffer, 1μL of T4 ligase, 4μL of ddH2O, and the reaction solution was prepared and connected at 16℃ for 16h. After culturing in ampicillin-containing medium for 12h, the bacteria were picked and sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing.

[0041] 3. Construction of Lentivirus

[0042] The pLVX-IRES-puro-PIWIL1 lentiviral vector and the lentiviral packaging auxiliary vector psPAX2 plasmid and pMD2.G plasmid were co-transfected into human embryonic kidney HEK-293T cells at the same time, and the virus was packaged in the cells. The packaged virus was secreted into the culture medium outside the cells, and the culture medium was collected and centrifuged to obtain the supernatant. The supernatant was filtered and centrifuged to obtain the yak PIWIL1 gene overexpression lentivirus.

[0043] The lentivirus constructed by the same method but using the pLVX-IRES-puro empty vector plasmid instead of the pLVX-IRES-puro-PIWIL1 plasmid was used as the negative control virus.

[0044] Example 2 Transfection of yak Leydig cells

[0045] The yak testicular interstitial cells in the logarithmic growth phase were digested with trypsin and prepared into a cell suspension (cell density was about 5×10 1 / mL) and then inoculated in a 6-well plate and cultured until the cell confluence reached about 30%. According to the multiplicity of infection (MOI) value, an appropriate amount of lentivirus was added (the MOI of PIWIL1 silencing lentivirus was 10, and the MOI of negative control lentivirus was 2.5), and the culture medium was replaced after 12 hours of culture. If there was no obvious cytotoxic effect, the culture medium was replaced after 24 hours of continuous culture. The yak testicular interstitial cells with lentivirus constructed by pLVX-IRES-puro-PIWIL1 plasmid and negative control virus were called silencing group and control group, respectively.

[0046] Western blot was used to detect the silencing of PIWIL1 protein. The results are as follows Figure 1 As shown. Figure 1 It can be seen that the PIWIL1 protein expression level in the silencing group was significantly lower than that in the control group, indicating that the target has a significant knockdown effect on the expression of the PIWIL1 gene at the protein level and is an effective target site.

[0047] Example 3 Verification of functional changes in bovine Leydig cells after PIWIL1 silencing

[0048] The inventors further verified the changes in protein levels in bovine Leydig cells after PIWIL1 silencing.

[0049] 1. Protein Extraction

[0050] Thaw the lysate at room temperature in advance, estimate the volume required for the experiment, and mix it with 1% PMSF for later use.

[0051] According to the mass and volume of each sample, add the corresponding volume of lysate sample, and then continue to stand on ice for 5 minutes.

[0052] Turn on the low-temperature refrigerated centrifuge, centrifuge at 12000 rpm, 4°C for 10 min, and separate the supernatant as the obtained protein extract.

[0053] 2. Protein Quantification

[0054] (1) Preparation of standard curve

[0055] A 0.5 μg / μL BSA protein standard solution was dispensed into each well of the ELISA plate in volumes of 0, 1, 2, 4, 8, 12, 16, and 20 μL, and the remaining volume was filled up to 20 μL with PBS buffer.

[0056] (2) Preparation of protein test solution

[0057] 1 μL of the sample protein extract to be tested was mixed with 19 μL of PBS buffer.

[0058] BCA reaction: According to the volume ratio of A liquid: B liquid of 50:1, estimate the volume of BCA working solution required for this experiment at 200 μL per well. Add the prepared working solution to each well, pipette repeatedly to mix thoroughly, and place at 37°C for 20 minutes. At this time, the solution changes from green to purple.

[0059] (3) Data reading

[0060] Start the ELISA instrument to preheat 15 minutes in advance, place the ELISA plate on the stage, set the reading wavelength to 570nm, and record the data.

[0061] A standard curve was drawn with the standard protein concentration and the corresponding absorbance value, and the sample protein concentration was calculated by the regression equation and multiplied by the dilution factor to obtain the protein concentration of the sample.

[0062] 3.SDS-PAGE

[0063] (1) Assembling the electrophoresis apparatus

[0064] After the cleaned glass plates are dried with filter paper, they are allowed to dry at room temperature. After confirming that there are no water stains or dust on the surface, assembly can begin. The long plate is on the outside, the short plate is on the inside, the bottom edges are aligned, and fixed with wedges. The bottom edges are sealed, and the two sides are clamped before glue injection can begin.

[0065] (2) Polyacrylamide gel preparation

[0066] Select the polyacrylamide gel of the corresponding concentration according to the molecular weight of the target protein. In this embodiment, the concentration of concentrated gel is 5%, and the concentration of separation gel is 8%, 10%, and 13%. The order of gel pouring is from bottom to top. Prepare the separation gel first, add APS and TEMED before pouring, mix well, pour along one side of the glass plate, and seal the upper layer with water to promote gel polymerization; after the separation gel is polymerized, pour out the water layer, pour in the prepared concentrated gel, add APS and TEMED before pouring, and finally seal with a comb, wait for about 30 minutes, then pull out the comb and start loading. The formula of polyacrylamide of each concentration is shown in Table 1:

[0067] Table 1 Polyacrylamide gel formula

[0068] Glue concentration <![CDATA[ddH 2 O(mL)]]> 30% gel stock solution Gelbuffer 10% SDS 5% 5.7 1.7 2.5 0.1 8% 4.7 2.7 2.5 0.1 10% 4.1 3.3 2.5 0.1 13% 3.1 4.3 2.5 0.1

[0069] Note: Use separation gel buffer when preparing separation gel; use stacking gel buffer when preparing stacking gel;

[0070] (3) Preparation of protein loading solution

[0071] The protein sample was diluted with 5× Loading Buffer and PBS, and boiled in a boiling water bath for 5 min to prepare a loading solution for use. The loading volume of this example was 20 μL, containing 40 μg of protein.

[0072] (4)SDS-PAGE

[0073] After pulling out the comb, inject electrophoresis liquid into the positive and negative electrodes of the electrophoresis tank respectively, add 20μl electrophoresis loading liquid to each well, and finally add 5μl protein Marker, connect the electrodes, adjust the current to the maximum, the voltage to 80V, and perform constant voltage electrophoresis for 2.5h.

[0074] 4. Transfer

[0075] (1) Preparation

[0076] First, after the transfer buffer is prepared, it should be pre-cooled in a 4°C refrigerator; second, when the electrophoresis is about to end, immerse the filter paper, sponge, etc. used for transfer in the transfer buffer and fully wet them; finally, cut a PVDF membrane of appropriate size, mark the front corners of the membrane, soak it with anhydrous methanol, and then immerse it in the transfer buffer and shake it on a shaker.

[0077] (2) Preparation of "Sandwich"

[0078] After electrophoresis, take out the glass plate, open it with a blade, cut off the concentrated gel part of the gel and the bottom of the separation gel, peel the remaining whole piece of gel into a container filled with transfer buffer and soak it for 10 minutes; first put a layer of sponge on the negative side of the transfer clip, then put 5 layers of filter paper, then put in the gel, and then the PVDF membrane. The front of the membrane should be in contact with the gel at this time, and finally put 5 layers of filter paper and a layer of sponge on the PVDF; forming a "sandwich" shape of "sponge-filter paper-membrane-gel-filter paper-sponge".

[0079] After the "sandwich" is laid out, clamp the transfer clip, insert it into the transfer tank, inject a sufficient amount of transfer buffer, connect the electrodes, adjust the current to the maximum, and transfer at a voltage of 80V for 1.5 hours.

[0080] 5. Closure

[0081] (1) Prepare 5% (M / V) skimmed milk powder with TBST buffer for later use.

[0082] (2) After the transfer is completed, remove the PVDF membrane, immerse it in TBST, and shake it on a shaker for 5 minutes.

[0083] (3) Pour off the TBST, immerse the PVDF membrane in the skimmed milk powder solution, and shake it slowly on a shaker for 1 h.

[0084] 6. Incubation with primary antibody

[0085] (1) Dilute the antibody with 5% (M / V) skim milk powder to prepare the antibody working solution.

[0086] (2) Pour the antibody working solution into the hybridization bag, put in the sealed PVDF membrane, seal it with a laminator, and perform antibody incubation according to Table 2.

[0087] Table 2 Primary antibody incubation conditions

[0088] Primary Antibody Name Dilution ratio Incubation conditions STAR Antibodies 1:500 4℃ overnight CYP11A1 Antibodies 1:200 4℃ overnight GAPDH Antibody 1:1000 4℃ overnight

[0089] 7. Incubation with secondary antibody

[0090] (1) After incubation with the primary antibody, the PVDF membrane was removed from the hybridization bag, immersed in TBST, and shaken on a shaker for 5 min. This step was repeated 4 times.

[0091] (2) Dilute the antibody with 5% (M / V) skim milk powder to prepare the secondary antibody working solution.

[0092] (3) Pour the secondary antibody working solution into the hybridization bag, put in the rinsed PVDF membrane, seal it with a laminator, and perform antibody incubation according to Table 3.

[0093] Table 3 Secondary antibody incubation conditions

[0094] Primary Antibody Name Secondary Antibody Name Dilution ratio Incubation conditions STAR Antibodies Goat anti-rabbit IgG-HRP 1:5000 37℃45min CYP11A1 Antibodies Goat anti-rabbit IgG-HRP 1:5000 37℃45min GAPDH Antibody Goat anti-rabbit IgG-HRP 1:5000 37℃45min

[0095] 8. ECL substrate luminescence

[0096] (1) After incubation with secondary antibody, the PVDF membrane was taken out of the hybridization bag, immersed in TBST, and shaken on a shaker for 5 min. This step was repeated 6 times.

[0097] (2) Mix equal volumes of ECL chemiluminescent reagents A and B for later use.

[0098] (3) Spread a piece of plastic wrap on the table, absorb the moisture on the back of the PVDF with filter paper, then spread it on the plastic wrap, sprinkle the ECL luminescent liquid evenly, and let it react for 5 minutes.

[0099] (4) Cover it with another piece of plastic wrap, use a glass rod to remove excess liquid, then transfer it to a dark box and expose it in a darkroom.

[0100] 9. Results Analysis

[0101] The film was scanned and the optical density of the target band was analyzed using the gel image processing system (Gel-Pro-Analyzer software). Figure 2 As shown. Figure 2 It can be seen that after interfering with the expression of the PIWIL1 gene, the protein expression levels of the key enzymes STAR and CYP11A1 for testosterone synthesis were significantly reduced, indicating that knockdown of the PIWIL1 gene can inhibit testosterone synthesis in yak Leydig cells, and the PIWIL1 gene can serve as an important target gene for regulating the function of yak Leydig cells.

[0102] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A siRNA for inhibiting the expression of yak PIWIL1 gene, characterized in that: The sequence of the siRNA is as follows: GAACCUAGAUCAUGUGGAAAGA.

2. A shRNA sequence capable of forming the siRNA according to claim 1, characterized in that: The sequence of the shRNA is as follows: GAACCUAGAUCAUGUGGAAAGATCTCTTTUAATCTTTCACATUATCTAUUTTC.

3. A gene sequence encoding the shRNA according to claim 2, characterized in that: The gene sequence is as follows: CCGGAACCTAGATCATGTGAAAGATTCAAGAGATCTTTCACATGATCTAGGTTCTTTTT.

4. A construction vector, characterized in that: Comprising the gene sequence described in claim 3.

5. A recombinant lentivirus, characterized in that: Comprising the vector of claim 4.

6. The recombinant lentivirus according to claim 5, characterized in that The recombinant lentivirus is obtained by co-transfecting mammalian cells with the vector according to claim 4, a viral packaging helper plasmid psPAX2 and a viral packaging helper plasmid pMD2.G.

7. Use of the siRNA according to claim 1, the shRNA according to claim 2, the gene sequence according to claim 3, the construction vector according to claim 4 and / or the recombinant lentivirus according to any one of claims 5-6 in the preparation of an inhibitor for inhibiting the testosterone synthesis ability of yaks.

8. The use according to claim 7, characterized in that: The inhibitor inhibits the testosterone synthesis ability of yaks by inhibiting the expression of STAR and CYP11A1.